Ezetimibe decreases serum amyloid A levels in HDL3 in hemodialysis patients

Clinical Nephrology

Volumn 74, Issue 4, 2010, Pages 282-287

  Hirano, T ^a   Nohtomi, K ^a   Nakanishi, N ^a   Watanabe, T ^a   Hyodo, T ^b   Taira, T ^b  

^a SHOWA UNIVERSITY   (Japan)

^b Yokohama Dai ichi Hospital   (Japan)

Author keywords

End stage renal disease patients; Ezetimibe; HDL subspecies; Hemodialysis; Serum amyloid A

Indexed keywords

APOLIPOPROTEIN B; EZETIMIBE; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERUM AMYLOID A; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MALE;

EID: 77957687489     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp74282     Document Type: Article

References (36)

1. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006; 58: 342-374.
2. Malle E, Steinmetz A, Raynes JG. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis. 1993; 102: 131-146.
3. Hoffman JS, Benditt EP. Changes in high density lipoprotein content following endotoxin administration in the mouse: formation of serum amyloid protein-rich subfractions. J Biol Chem. 1982; 257: 10510-10517.
4. Marhaug G, Sletten K, Husby G. Characterization of amyloid related protein SAA complexed with serum lipoproteins (apoSAA). Clin Exp Immunol. 1982; 50: 382-389. (Pubitemid 12004868)
5. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism:mechanismsand consequences to the host. J Lipid Res. 2004; 45: 1169-1196. (Pubitemid 38802622)
6. Esteve E, Ricart W, Fernandez-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr. 2005; 24: 16-31.
7. Libetta C, De Nicola L, Rampino T, De Simone W, Memoli B. Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation. Kidney Int. 1996; 49: 506-511. (Pubitemid 26050327)
8. Tsirpanlis G, Bagos P, Ioannou D, Bleta A, Marinou I, Lagouranis A, Chatzipanagiotou S, Nicolaou C. The variability and accurate assessment of microinflammation in haemodialysis patients. Nephrol Dial Transplant. 2004; 19: 150-157. (Pubitemid 38072626)
9. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes fromhuman serum. JLipid Res. 1981; 22: 339-358. (Pubitemid 11125137)
10. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004; 303: 1201-1204.
11. Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, Durrington PN, Chilcott J. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009; 265: 568-580.
12. Attman PO, Samuelsson O. Dyslipidemia of kidney disease. Curr Opin Lipidol. 2009; 20: 293-299.
13. Türk TR, Voropaeva E, Kohnle M, Nürnberger J, Philipp T, Kribben A, Heemann U, Witzke O. Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol Dial Transplant. 2008; 23: 369-373.
14. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005; 44: 467-494. (Pubitemid 40733733)
15. Hirano T, Nohtomi K, Koba S, Muroi A, Ito Y. A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay. J Lipid Res. 2008; 49: 1130-1136.
16. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res. 1978; 19: 65-76. (Pubitemid 8268303)
17. Miyauchi K, Kayahara N, Ishigami M, Kuwata H, Mori H, Sugiuchi H, Irie T, Tanaka A, Yamashita S, Yamamura T. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem. 2007; 53: 2128-2135.
18. Benditt E. Serum amyloid A protein. Meth Enzymol. 1988; 163: 511-523.
19. Nagasaki T, Akanuma Y. A new colorimetric method for the determination of plasma lecithin-cholesterol acyltransferase activity. Clin Chim Acta. 1977; 75: 371-375.
20. Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis: a strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb. 1991; 11: 174-182.
21. Drexel H, Amann FW, Rentsch K, Neuenschwander C, Luethy A, Khan SI, Follath F. Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol. 1992; 70: 436-440.
22. Skinner ER. High-density lipoprotein subclasses. Curr Opin Lipidol. 1994; 5: 241-247.
23. Barter P, Kastelein J, Nunn A, Hobbs R. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis. 2003; 168: 195-211. (Pubitemid 36703318)
24. Desai MY, Rodriguez A, Wasserman BA, Gerstenblith G, Agarwal S, Kennedy M, Bluemke DA, Lima JAC. Association of cholesterol subfractions and carotid lipid core measured by MRI. Arterioscler Thromb Vasc Biol. 2005; 25: 110-111.
25. Ohta T, Saku K, Takata K, Nakamura R, Ikeda Y, Matsuda I. Different effects of subclasses of HDL containing apoA-I but not apoA-II (LpA-I) on cholesterol esterification in plasma and net cholesterol efflux from foam cells. Arterioscler Thromb Vasc Biol. 1995; 15: 956-962.
26. Duriez P, Fruchart JC. High-density lipoprotein subclasses and apolipoprotein A-I. Clin Chim Acta. 1999; 286: 97-114. (Pubitemid 29406103)
27. Parks JS, Rudel LL. Alteration of high density lipoprotein subfraction distribution with induction of serum amyloid A protein (SAA) in the nonhuman primate. J Lipid Res. 1985; 26: 82-91.
28. Coetzee GA, Strachan AF, van derWesthuyzen DR, Hoppe HC, Jeenah MS, de Beer FC. Serum amyloid A-containing human high density lipoprotein 3: density, size, and apolipoprotein composition. J Biol Chem. 1986; 261: 9644-9651.
29. Cabana VG, Lukens JR, Rice KS, Hawkins TJ, Getz GS. HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. J Lipid Res. 1996; 37: 2662-2674. (Pubitemid 27051512)
30. Ohta T, Nakamura R, Ikeda Y, Shinohara M, Miyazaki A, Horiuchi S, Matsuda I. Differential effect of subspecies of lipoprotein containing apolipoprotein A-I on cholesterol efflux from cholesterol- loaded macrophages: functional correlation with lecithin: cholesterol acyltransferase. Biochim Biophys Acta. 1992; 1165: 119-128.
31. Staprans I, Pan XM, Rapp JH, Moser AH, Feingold KR. Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins. J Lipid Res. 2006; 47: 2575-2580. (Pubitemid 44936118)
32. Cabana VG, Siegel JN, Sabesin SM. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res. 1989; 30: 39-49.
33. Hoffman JS, Benditt EP. Plasma clearance kinetics of the amyloid-related high density lipoprotein apoprotein, serum amyloid protein (apoSAA), in the mouse: evidence for rapid apoSAA clearance. J Clin Investig. 1983; 71: 926-934.
34. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E, ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358: 1431-1443.
35. Fleg JL, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, Silverman A, Galloway JM, Henderson JA, Weir MR, Wilson C, Stylianou M, Howard WJ. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008; 52: 2198-2205.
36. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int. 2003; 63: 207-210.